🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

448 results for “RAD” Clear

  1. GADOTERIC ACID, [18F]fludarabine

    Pari Pharma GmbH

    Patients with newly diagnosed primary central nervous system lymphoma naïve to surgery, radiotherapy or chemotherapy

    phase 2 small molecule active

    1 trial

  2. GR1014 Cutaneous Gel, The placebo ingredients are identical to those of GR1014-CG with the exception that the drug substance (amifostine) and hydrochloric acid (used at the hydrolysis step to convert amifostine in the active substance, amifostine thiol) are omitted.

    Lacuna Pharma Pty Ltd

    Radiation-induced dermatitis (radiodermatitis)

    phase 2 small molecule active

    1 trial

  3. Genoxal 200 mg polvo para solución inyectable y para perfusión, Fludarabina Teva 25 mg/ml concentrado para solución para perfusión o inyección EFG, AUTO1, Paracetamol MABO 500 mg comprimidos

    Autolus GmbH

    Relapsed or refractory B cell acute lymphoblastic leukaemia

    phase 2 small molecule active

    1 trial

  4. Gocovri (extended-release amantidine)

    SUPERNUS PHARMACEUTICALS, INC.

    Radiation Encephalopathy

    phase 2 small molecule active

    1 trial

  5. HYDROXYCARBAMIDE , BEVACIZUMAB , SUNITINIB , OCTREOTIDE , EVEROLIMUS , Lutathera 370 MBq/mL solution for infusion

    Ningbo Cancer Hospital

    Recurrent Meningioma without local treatment options (Surgery or Radiotherapy)

    phase 2 small molecule active

    1 trial

  6. High-Low Dose Radiotherapy

    Jian Li

    Nasopharyngeal Carcinoma (NPC)

    phase 2 other active

    1 trial

  7. Hydrogel of spirulina-derived exosomes.

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Radiation-induced Esophagitis

    phase 2 small molecule active

    1 trial

  8. Hypofractionated radiation/chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer

    phase 2 other completed

    1 trial

  9. IL-6 aGVHD Siltuximab: A phase II study to assess the efficacy and tolerability of siltuximab plus corticosteroids in first line treatment of grade III/IV acute graft versus host disease of the liver of/and the gastro-intestinal tract.

    Disc Medicine

    Grade III/IV acute graft versus host disease of the liver of/and the gastro-intestinal tract

    phase 2 other active

    1 trial

  10. IMFINZI 50 mg/mL concentrate for solution for infusion.

    The George Institute

    unresectable stage III NSCLC (Non–small-cell lung cancer)

    phase 2 small molecule active

    1 trial

  11. IMFINZI 50 mg/mL concentrate for solution for infusion., FLUOROURACIL, FOLINIC ACID, OXALIPLATIN

    Ningbo Cancer Hospital

    Localised unresectable adenocarcinoma or squamous cell carcinoma of the oesophagus without any prior chemotherapy, surgery, or radiotherapy

    phase 2 small molecule active

    1 trial

  12. INF904

    InflaRx GmbH

    Moderate to Severe Chronic Spontaneous Urticaria (CSU) or Moderate to Severe Hidradenitis Suppurativa (HS)

    phase 2 small molecule active

    1 trial

  13. Immunization with P. vivax irradiated sporozoites

    BRIGHT MINDS BIOSCIENCES INC.

    Malaria

    phase 2 mab completed

    1 trial

  14. Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Hidradenitis Suppurativa

    phase 2 mab completed

    1 trial

  15. Injectable suspension of allogeneic adult mesenchymal stem cells

    Lxo Ireland Designated Activity Company

    Hidradenitis Suppurativa

    phase 2 mab active

    1 trial

  16. Intensity-modulated radiation therapy (IMRT) in combination with fluzoparib, abiraterone acetate tablets (II), and prednisone.

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Castration-resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  17. Isradipine

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Dependence

    phase 2 small molecule completed

    1 trial

  18. JEMPERLI 500 mg concentrate for solution for infusion, Zejula 100 mg film-coated tablets

    The George Institute

    DNA repair-deficient or platinum-sensitive solid tumors

    phase 2 small molecule active

    1 trial

  19. JMT108

    Shanghai University of Traditional Chinese Medicine

    Unresectable Locally Advanced or Metastatic Melanoma

    phase 2 small molecule active

    1 trial

  20. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Fondazione Telethon ETS

    high-risk soft tissue sarcoma of the extremity (undifferentiated pleomorphic sarcoma or dedifferentiated/pleomorphic liposarcoma, tumor size > 5 cm, grade 2 or 3 out of 3)

    phase 2 small molecule active

    1 trial

  21. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Fondazione Telethon ETS

    Patients with pre neoplastic high grade HPV-related vulvar and cervical lesions

    phase 2 small molecule active

    1 trial

  22. LAD328, SODIUM CHLORIDE

    Almirall, S.A.

    moderate-to-severe hidradenitis suppurativa

    phase 2 small molecule active

    1 trial

  23. LDE225 0.75%

    Novartis Pharmaceuticals

    Sporadic Superficial and Nodular Skin Basal Cell Carcinomas

    phase 2 small molecule terminated

    1 trial

  24. LENVATINIB, KEYTRUDA 25 mg/mL concentrate for solution for infusion.

    Disc Medicine

    high risk or poor response after chemoradiation and brachytherapy for locally advanced cervix cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources